Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.

Investigational new drugs - 1 Feb 2011

Steeghs Neeltje, Gelderblom Hans, Wessels Judith, Eskens Ferry A L M, de Bont Natasja, Nortier Johan W R, Guchelaar Henk-Jan

Abstract excerpt

PURPOSE: Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR; VEGFR-2) and fms-related tyrosine kinase 4 (FLT4; VEGFR-3). This study aims at the identification of relationships between single nucleotide polymorphisms (SNPs) in genes encodin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Dose-Response Relationship, Drug
Share to Pharmacogenetics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Pyridazines

Share to Pyridines

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Vascular Endothelial Growth Factor Receptor-3

Source

Open in PubMed Open full text

Identifiers

PMID: 19924384
DOI: 10.1007/s10637-009-9347-0
PMCID: PMC3016151

Genes

FLT4
KDR
ABCB1
ABCC1
ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-19924384-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.PMID 19924384Read ↗

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.Semantic proximity Read ↗

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.Semantic proximity Read ↗

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.Semantic proximity Read ↗

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.Semantic proximity Read ↗

Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.Semantic proximity Read ↗

Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis.Semantic proximity Read ↗

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.Semantic proximity Read ↗

Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.Semantic proximity Read ↗

Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.